Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of NEC Corporation.

    Client Virtual Booth

    NEC CORPORATION

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    NEC Corporation
    japan Flag
    Country
    Country
    Japan
    Address
    Address
    7-1, Shiba 5-chome Minato-ku, Tokyo 108-8001
    Telephone
    Telephone
    +81-3-3454-1111
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.nec.com/en/global/solutions/ai-drug/index.html
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (Myvac® Platform)

    Details:

    First patient with head and neck cancer has been dosed with the Company’s innovative individualized immunotherapy, TG4050. The vaccine is based on Transgene’s myvac® technology platform, which leverages cutting-edge AI capabilities to customize the treatment for each patient.


    Lead Product(s): TG4050

    Therapeutic Area: Oncology Product Name: TG4050

    Highest Development Status: Phase IProduct Type: Vaccine

    Recipient: Transgene

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 21, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    NEC Publishes Design Blueprints for SARS-Cov-2 Vaccines Using its Artificial Intelligence Technology

    Details:

    These AI prediction platforms are based on the AI technology used by NEC and NOI in the development of personalized neoantigen cancer vaccines.


    Lead Product(s): SARS-CoV-2 vaccine

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: UndisclosedProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 23, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-05-06

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search